Survival analyses
| Second-line treatment . | Single-agent anti-CD20 Ab or RT alone, N = 37 . | CT ± anti-CD20 Ab ± RT, N = 27 . | HDCT + ASCT, N = 31 . | Total, N = 99 . |
|---|---|---|---|---|
| MOT-2, y | 3.8 | 4.6 | 6.7 | 4.6 |
| Second relapse, n (%) | 8 (21) | 3 (12) | 3 (10) | 14 (14) |
| Third relapse, n (%) | 3 (8) | — | — | 3 (3) |
| PFS-2, % (95% CI) | ||||
| 3-y estimate | 74.1 (58.5-89.7) | 78.4 (61.6-95.3) | 89.8 (78.9-100) | 80.9 (72.5-89.4) |
| 5-y estimate | 74.1 (58.5-89.7) | 68.0 (48.1-87.9) | 84.6 (70.2-98.9) | 75.6 (65.7-85.5) |
| OS-2, % (95% CI) | ||||
| 3-y estimate | 97.2 (91.9-100) | 83.3 (68.4-98.2) | 89.8 (78.9-100) | 91.1 (85.2-97.0) |
| 5-y estimate | 97.2 (91.9-100) | 77.8 (60.3-95.2) | 89.8 (78.9-100) | 89.5 (82.9-96.1) |
| Second-line treatment . | Single-agent anti-CD20 Ab or RT alone, N = 37 . | CT ± anti-CD20 Ab ± RT, N = 27 . | HDCT + ASCT, N = 31 . | Total, N = 99 . |
|---|---|---|---|---|
| MOT-2, y | 3.8 | 4.6 | 6.7 | 4.6 |
| Second relapse, n (%) | 8 (21) | 3 (12) | 3 (10) | 14 (14) |
| Third relapse, n (%) | 3 (8) | — | — | 3 (3) |
| PFS-2, % (95% CI) | ||||
| 3-y estimate | 74.1 (58.5-89.7) | 78.4 (61.6-95.3) | 89.8 (78.9-100) | 80.9 (72.5-89.4) |
| 5-y estimate | 74.1 (58.5-89.7) | 68.0 (48.1-87.9) | 84.6 (70.2-98.9) | 75.6 (65.7-85.5) |
| OS-2, % (95% CI) | ||||
| 3-y estimate | 97.2 (91.9-100) | 83.3 (68.4-98.2) | 89.8 (78.9-100) | 91.1 (85.2-97.0) |
| 5-y estimate | 97.2 (91.9-100) | 77.8 (60.3-95.2) | 89.8 (78.9-100) | 89.5 (82.9-96.1) |
— , no patients meet the respective criteria.